Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03981796 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

A Phase 3 study of Neoplasms, sponsored by Tesaro.

Active
Registry status
Phase 3
Development phase
785
Enrollment target
20
Study locations

NCT03981796 is a Phase 3 study of Neoplasms that is active but no longer recruiting, run by Tesaro. The registered enrollment target is 785 participants, below the 1,616-participant average among 158 other Neoplasms trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03981796, a Phase 3 study of Neoplasms, is active but no longer recruiting, sponsored by Tesaro.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
785 participants
Enrollment target
20
Study locations

Study Summary

This is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo plus carboplatin-paclitaxel followed by placebo in participants with recurrent or primary advanced (Stage III or IV) endometrial cancer.

Conditions Studied

Neoplasms

Interventions

  • DRUG Carboplatin
  • DRUG Paclitaxel
  • DRUG Niraparib
  • BIOLOGICAL Dostarlimab
  • DRUG Placebo matching dostarlimab

Study Locations (20)

Florida

  • GSK Investigational Site - Deerfield Beach
  • GSK Investigational Site - Jacksonville
  • GSK Investigational Site - Miami
  • GSK Investigational Site - Miami
  • GSK Investigational Site - Orlando

Arizona

  • GSK Investigational Site - Phoenix
  • GSK Investigational Site - Scottsdale
  • GSK Investigational Site - Tucson
  • GSK Investigational Site - Tucson

Georgia

  • GSK Investigational Site - Atlanta
  • GSK Investigational Site - Augusta
  • GSK Investigational Site - Savannah

Indiana

  • GSK Investigational Site - Fort Wayne
  • GSK Investigational Site - Indianapolis
  • GSK Investigational Site - Indianapolis

California

  • GSK Investigational Site - Newport Beach
  • GSK Investigational Site - Palo Alto

Illinois

  • GSK Investigational Site - Hinsdale
  • GSK Investigational Site - Zion

Iowa

  • GSK Investigational Site - Iowa City

Trial Details

FieldValue
Enrollment Target 785 participants
Start Date 2019-07-18
Est. Completion 2026-11-26
Phase Phase 3

Sponsor

Tesaro

26 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03981796

The ClinicalTrials.gov registry entry for NCT03981796 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 785 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,616-participant average among 158 other Neoplasms trials with a reported enrollment target (51% lower). The listed sponsor is Tesaro, which has 26 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT03981796 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Arizona, Georgia.

Frequently Asked Questions

What is clinical trial NCT03981796 about?

NCT03981796 is a clinical study titled "A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer". This is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel follow...

What is the current status of trial NCT03981796?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 785 participants. The study started on 2019-07-18. Estimated completion is 2026-11-26.

What conditions does trial NCT03981796 study?

This clinical trial studies the following conditions: Neoplasms.

What interventions are being tested in trial NCT03981796?

The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Niraparib (DRUG), Dostarlimab (BIOLOGICAL), Placebo matching dostarlimab (DRUG).

Who is sponsoring clinical trial NCT03981796?

This trial is sponsored by Tesaro, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03981796 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.